DB05740ExperimentalSmall molecule
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral...
- Mechanism
- Curator reviewed
RPI-78M contains anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect.
- Primary indication
- Investigated for use/treatment in multiple sclerosis, neurologic disorders, and pain (acute or chronic).Curator reviewed
- Code names
- RPI-78M
Resolves to
What you can answer from here — as of April 02, 2025
6Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with RPI-78M, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account